Genprex Achieves Multiple Clinical Development Milestones in 2025 Lung Cancer Trials

Genprex has achieved multiple clinical development milestones in 2025, with patient treatment continuing in two lung cancer clinical trials. The company has issued a stockholder letter and corporate update outlining key milestones for 2025 and beyond, including progress across its oncology and diabetes programs. Genprex aims to transform the lives of patients battling cancer and diabetes through its gene therapy technology.

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, has made significant progress in its oncology and diabetes programs, as outlined in a recent stockholder letter and corporate update. The company, based in Austin, Texas, continues patient treatment in two lung cancer clinical trials and has outlined key milestones for 2025 and beyond.

The stockholder letter, issued on August 4, 2025, summarized Genprex's achievements across its technology programs. Ryan Confer, President and Chief Executive Officer, expressed enthusiasm about the company's future, emphasizing the importance of maintaining streamlined, focused strategies to build value across the entire organization [1].

Genprex's oncology program uses its Oncoprex Delivery System, which encapsulates gene-expressing plasmids using lipid-based nanoparticles. The lead product candidate, Reqorsa Gene Therapy, is being evaluated in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) treatment. Both lung cancer clinical programs have received Fast Track Designation from the FDA, and the SCLC program has received FDA Orphan Drug Designation [1].

For diabetes treatment, Genprex's approach uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. The GPX-002 therapy aims to transform alpha cells into functional beta-like cells for Type 1 diabetes and rejuvenate beta cells for Type 2 diabetes [1].

In a separate development, Mayo Clinic researchers discovered that a sugar molecule used by cancer cells to hide from the immune system might also protect insulin-producing beta cells in type 1 diabetes. By engineering these cells with the same sugar molecule—sialic acid—they prevented immune attacks in lab models, potentially transforming treatment options for type 1 diabetes [2].

Genprex's progress in gene therapy technology and the Mayo Clinic's breakthrough in diabetes treatment underscore the potential for significant advancements in cancer and diabetes therapies. The company remains dedicated to transforming the lives of patients battling these diseases through its novel gene therapies.

References:
[1] https://www.streetinsider.com/Corporate+News/Genprex+issues+stockholder+letter+with+2025+corporate+update/25140259.html
[2] https://www.sciencedaily.com/releases/2025/08/250802022917.htm